SEC Tracker
Get the app

Corbus Pharmaceuticals Holdings CRBP

Corbus Pharmaceuticals Holdings reported a net loss of $37.75 million

Corbus Pharmaceuticals Holdings (CRBP) filed a 10-Q with the SEC on Nov 10, 2026, 4:35 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Net loss: $37.75 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$4.87 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $30.25 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Corbus Pharmaceuticals Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

1 new risk factor

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$38.82M−$36.19M−7.3%
Net income−$37.75M−$35.04M−7.8%
Operating cash flow−$21.24M−$29.63M+28%
Cash$30.25M$23.37M+29%
New risk factors (1)
  • Significant disruptions of information technology systems or breaches of data security could materially adversely affect our business, results of operations and financial condition. +7 more paragraphs

Data on this page was fetched . The filing on SEC.gov is the record.